86 related articles for article (PubMed ID: 12692614)
1. Retrospective appraisal of busulfan dose adjustment in children.
Dupuis LL; Najdova M; Saunders EF
Bone Marrow Transplant; 2003 Apr; 31(8):729. PubMed ID: 12692614
[No Abstract] [Full Text] [Related]
2. Retrospective appraisal of busulfan dose adjustment in children.
Dupuis LL; Najdova M; Saunders EF
Bone Marrow Transplant; 2000 Dec; 26(11):1143-7. PubMed ID: 11149723
[TBL] [Abstract][Full Text] [Related]
3. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.
Zwaveling J; Bredius RG; Cremers SC; Ball LM; Lankester AC; Teepe-Twiss IM; Egeler RM; den Hartigh J; Vossen JM
Bone Marrow Transplant; 2005 Jan; 35(1):17-23. PubMed ID: 15502853
[TBL] [Abstract][Full Text] [Related]
4. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG
Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185
[TBL] [Abstract][Full Text] [Related]
5. Pretransplant conditioning in adults and children: dose assurance with intravenous busulfan.
Fisher VL; Barnes YJ; Nuss SL
Oncol Nurs Forum; 2006 Nov; 33(2):E36-43. PubMed ID: 16518436
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
[TBL] [Abstract][Full Text] [Related]
7. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.
Vassal G; Michel G; Espérou H; Gentet JC; Valteau-Couanet D; Doz F; Mechinaud F; Galambrun C; Neven B; Zouabi H; Nguyen L; Puozzo C
Cancer Chemother Pharmacol; 2008 Jan; 61(1):113-23. PubMed ID: 17393167
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
[TBL] [Abstract][Full Text] [Related]
9. A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantation.
Hoffer E; Akria L; Tabak A; Scherb I; Rowe JM; Krivoy N
Ther Drug Monit; 2004 Jun; 26(3):331-5. PubMed ID: 15167637
[TBL] [Abstract][Full Text] [Related]
10. Busulfan in children: impact of development on dose-exposure-response relationship?
Dalal J; Neville KA
Pediatr Blood Cancer; 2010 Feb; 54(2):191-2. PubMed ID: 19953643
[No Abstract] [Full Text] [Related]
11. The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.
Bleyzac N
Fundam Clin Pharmacol; 2008 Dec; 22(6):605-8. PubMed ID: 19049662
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
Kletzel M; Jacobsohn D; Duerst R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
[TBL] [Abstract][Full Text] [Related]
13. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
Dupuis LL; Sibbald C; Schechter T; Ansari M; Gassas A; Théorêt Y; Kassir N; Champagne MA; Doyle J
Biol Blood Marrow Transplant; 2008 May; 14(5):576-82. PubMed ID: 18410900
[TBL] [Abstract][Full Text] [Related]
14. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study.
Bertholle-Bonnet V; Bleyzac N; Galambrun C; Mialou V; Bertrand Y; Souillet G; Aulagner G
Ther Drug Monit; 2007 Apr; 29(2):177-84. PubMed ID: 17417071
[TBL] [Abstract][Full Text] [Related]
15. Busulfan in hematopoietic stem cell transplant setting.
McCune JS; Holmberg LA
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):957-69. PubMed ID: 19611402
[TBL] [Abstract][Full Text] [Related]
16. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
17. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of oral busulfan in children.
Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
[TBL] [Abstract][Full Text] [Related]
19. High-dose busulfan and the risk of pulmonary mortality after autologous stem cell transplant.
Kalaycio M; Pohlman B; Kuczkowski E; Rybicki L; Andresen S; Sobecks R; Bolwell B
Clin Transplant; 2006; 20(6):783-7. PubMed ID: 17100730
[TBL] [Abstract][Full Text] [Related]
20. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies.
Williams CB; Day SD; Reed MD; Copelan EA; Bechtel T; Leather HL; Wingard JR; Abbott BL; Abhyankar S; McGuirk JP
Biol Blood Marrow Transplant; 2004 Sep; 10(9):614-23. PubMed ID: 15319773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
